Resveratrol protects against protease inhibitor-induced reactive oxygen species production, reticulum stress and lipid raft perturbation

AIDS

Volumn 24, Issue 10, 2010, Pages 1437-1447

  Touzet, Olivia ^a   Philips, Alexandre ^a  

^a INSERM   (France)

Author keywords

antioxidant; HIV; membrane microdomain; muscle skeletal; protease inhibitors

Indexed keywords

ATAZANAVIR; CAVEOLIN 3; FLOTILLIN 1; LOPINAVIR; NITROBLUE TETRAZOLIUM; PROTEINASE INHIBITOR; REACTIVE OXYGEN METABOLITE; RESVERATROL; RITONAVIR; SAQUINAVIR;

ANTIOXIDANT ACTIVITY; ARTICLE; BIOCHEMISTRY; CELL DAMAGE; CLINICAL ASSESSMENT; CONTROLLED STUDY; ELECTRON MICROSCOPY; ENDOPLASMIC RETICULUM STRESS; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOFLUORESCENCE; LIPID RAFT; MYOTUBE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SKELETAL MUSCLE;

ANTIOXIDANTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CELLS, CULTURED; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MUSCLE FIBERS, SKELETAL; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SARCOPLASMIC RETICULUM; STILBENES;

EID: 77953914488     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833a6114     Document Type: Article

References (49)

1. Hui DY. Effects of HIV protease inhibitor therapy on lipid metabolism. Prog Lipid Res 2003; 42:81-92.
2. Beregszaszi M, Jaquet D, Levine M, Ortega-Rodriguez E, Baltakse V, Polak M, Levy-Marchal C. Severe insulin resistance contrasting with mild anthropometric changes in the adipose tissue of HIV-infected children with lipohypertrophy. Int J Obes Relat Metab Disord 2003; 27:25-30.
3. Bongiovanni M, Bini T, Chiesa E, Cicconi P, Adorni F, Monforte d'Arminio A. Lopinavir/ritonavir vs. indinavir/ritona-vir in antiretroviral naive HIV-infected patients: immunovir-ological outcome and side effects. Antiviral Res 2004; 62:53-56.
4. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy, hyperli-pidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-F58.
5. Holmberg SD, Moorman AC, Greenberg AE. Trends in rates of myocardial infarction among patients with HIV. N Engl J Med 2004; 350:730-732; author reply 730-732.
6. Koster JC, Remedi MS, Qiu H, Nichols CG, Hruz PW. HIV protease inhibitors acutely impair glucose-stimulated insulin release. Diabetes 2003; 52:1695-1700.
7. Kohli R, Klein RS, Schoenbaum EE, Anastos K, Minkoff H, Sacks HS. Aging and HIV infection. J Urban Health 2006; 83:31-42.
8. Senior K. Growing old with HIV. Lancet Infect Dis 2005; 5: 739.
9. Mondal D, Pradhan L, Ali M, Agrawal KC. HAART drugs induce oxidative stress in human endothelial cells and increase en-dothelial recruitment of mononuclear cells: exacerbation by inflammatory cytokines and amelioration by antioxidants. Cardiovasc Toxicol 2004; 4:287-302.
10. Gills JJ, Lopiccolo J, Tsurutani J, Shoemaker RH, Best CJ, Abu-Asab MS, et al. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res 2007; 13:5183-5194.
11. Pyrko P, Kardosh A, Wang W, Xiong W, Schonthal AH, Chen TC. HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress. Cancer Res 2007; 67:10920-10928.
12. Chandra S, Mondal D, Agrawal KC. HIV-1 protease inhibitor induced oxidative stress suppresses glucose stimulated insulin release: protection with thymoquinone. Exp Biol Med (Maywood) 2009; 234:442-453.
13. Ben-Romano R, Rudich A, Etzion S, Potashnik R, Kagan E, Greenbaum U, Bashan N. Nelfinavir induces adipocyte insulin resistance through the induction of oxidative stress: differential protective effect of antioxidant agents. Antivir Ther 2006; 11:1051-1060.
14. Kraus M, Malenke E, Gogel J, Muller H, Ruckrich T, Overkleeft H, et al. Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apopto-sis. Mol Cancer Ther 2008; 7:1940-1948.
15. Zhou H, Pandak WM Jr, Lyall V, Natarajan R, Hylemon PB. HIV protease inhibitors activate the unfolded protein response in macrophages: implication for atherosclerosis and cardiovascular disease. Mol Pharmacol 2005; 68:690-700.
16. Kim I, Xu W, Reed JC. Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat Rev Drug Discov 2008; 7:1013-1030.
17. Fantini J, Garmy N, Mahfoud R, Yahi N. Lipid rafts: structure, function and role in HIV, Alzheimer's and prion diseases. Expert Rev Mol Med 2002; 4:1-22.
18. Wang MW, Wei S, Faccio R, Takeshita S, Tebas P, Powderly WG, et al. The HIV protease inhibitor ritonavir blocks osteo-clastogenesis and function by impairing RANKL-induced signaling. J Clin Invest 2004; 114:206-213.
19. Babuke T, Tikkanen R. Dissecting the molecular function of reggie/flotillin proteins. Eur J Cell Biol 2007; 86:525-532.
20. Bickel PE, Scherer PE, Schnitzer JE, Oh P, Lisanti MP, Lodish HF. Flotillin and epidermal surface antigen define a new family of caveolae-associated integral membrane proteins. J Biol Chem 1997; 272:13793-13802.
21. Morrow IC, Rea S, Martin S, Prior IA, Prohaska R, Hancock JF, et al. Flotillin-1/reggie-2 traffics to surface raft domains via a novel golgi-independent pathway. Identification of a novel membrane targeting domain and a role for palmitoylation. J Biol Chem 2002; 277:48834-48841.
22. Williams TM, Lisanti MP. The caveolin proteins. Genome Biol 2004; 5:214.
23. Dirks Naylor AJ. Cellular effects of resveratrol in skeletal muscle. Life Sci 2009; 84:637-640.
24. Penumathsa SV, Maulik N. Resveratrol: a promising agent in promoting cardioprotection against coronary heart disease. Can J Physiol Pharmacol 2009; 87:275-286.
25. Das DK, Maulik N. Resveratrol in cardioprotection: a therapeutic promise of alternative medicine. Mol Interv 2006; 6:36-47.
26. Imamura G, Bertelli AA, Bertelli A, Otani H, Maulik N, Das DK. Pharmacological preconditioning with resveratrol: an insight with iNOS knockout mice. Am J Physiol Heart Circ Physiol 2002; 282:H1996-H2003.
27. Ray PS, Maulik G, Cordis GA, Bertelli AA, Bertelli A, Das DK. The red wine antioxidant resveratrol protects isolated rat hearts from ischemia reperfusion injury. Free Radic Biol Med 1999; 27:160-169.
28. Bureau G, Longpre F, Martinoli MG. Resveratrol and quercetin, two natural polyphenols, reduce apoptotic neuronal cell death induced by neuroinflammation. J Neurosci Res 2008; 86:403-410.
29. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003; 425:191-196.
30. Sun W, Wang W, Kim J, Keng P, Yang S, Zhang H, et al. Anticancer effect of resveratrol is associated with induction of apoptosis via a mitochondrial pathway alignment. Adv Exp Med Biol 2008; 614:179-186.
31. Coisy-Quivy M, Touzet M, Bourret A, Hipskind RA, Mercier J, Fort P, Philips A. TC10 controls human myofibril organization and is activated by the sarcomeric RhoGEF obscurin. J. Cell Sci 2009; 122 (Pt 7):947-956.
32. Causeret M, Taulet N, Comunale F, Favard C, Gauthier-Rouviere C. N-cadherin association with lipid rafts regulates its dynamic assembly at cell-cell junctions in C2C12 myo-blasts. Mol Biol Cell 2005; 16:2168-2180.
33. Iwabuchi K, Handa K, Hakomori S. Separation of 'glycosphin-golipid signaling domain' from caveolin-containing membrane fraction in mouse melanoma B16 cells and its role in cell adhesion coupled with signaling. J Biol Chem 1998; 273: 33766-33773.
34. Caron M, Auclair M, Donadille B, Bereziat V, Guerci B, Laville M, et al. Human lipodystrophies linked to mutations in A-type lamins and to HIV protease inhibitor therapy are both associated with prelamin A accumulation, oxidative stress and premature cellular senescence. Cell Death Differ 2007; 14:1759-1767.
35. Coffinier C, Hudon SE, Farber EA, Chang SY, Hrycyna CA, Young SG, Fong LG. HIV protease inhibitors block the zinc metalloproteinase ZMPSTE24 and lead to an accumulation of prelamin A in cells. Proc Natl Acad Sci USA 2007; 104:13432-13437.
36. Coffinier C, Hudon SE, Lee R, Farber EA, Nobumori C, Miner JH, et al. A potent HIV protease inhibitor, darunavir, does not inhibit ZMPSTE24 or lead to an accumulation of farnesyl-prelamin A in cells. J Biol Chem 2008; 283:9797-9804.
37. Fong LG, Ng JK, Lammerding J, Vickers TA, Meta M, Cote N, et al. Prelamin A and lamin A appear to be dispensable in the nuclear lamina. J Clin Invest 2006; 116:743-752.
38. Fong LG, Ng JK, Meta M, Cote N, Yang SH, Stewart CL, et al. Heterozygosity for Lmna deficiency eliminates the progeria-like phenotypes in Zmpste24-deficient mice. Proc Natl Acad Sci USA 2004; 101:18111-18116.
39. Young SG, Fong LG, Michaelis S. Prelamin A, Zmpste24, misshapen cell nuclei, and progeria: new evidence suggesting that protein farnesylation could be important for disease pathogenesis. J Lipid Res 2005; 46:2531-2558.
40. Agarwal AK, Fryns JP, Auchus RJ, Garg A. Zinc metalloprotei-nase, ZMPSTE24, is mutated in mandibuloacral dysplasia. Hum Mol Genet 2003; 12:1995-2001.
41. Moulson CL, Go G, Gardner JM, van der Wal AC, Smitt JH, van Hagen JM, Miner JH. Homozygous and compound heterozygous mutations in ZMPSTE24 cause the laminopathy restrictive dermopathy. J Invest Dermatol 2005; 125:913-919.
42. Navarro CL, Cadinanos J, De Sandre-Giovannoli A, Bernard R, Courrier S, Boccaccio I, et al. Loss of ZMPSTE24 (FACE-1) causes autosomal recessive restrictive dermopathy and accumulation of Lamin A precursors. Hum Mol Genet 2005; 14:1503-1513.
43. Vincent S, Tourniaire F, El Yazidi CM, Compe E, Manches O, Plannels R, Roche R. Nelfinavir induces necrosis of 3T3F44-2A adipocytes by oxidative stress. J Acquir Immune Defic Syndr 2004; 37:1556-1562.
44. Viner RI, Ferrington DA, Williams TD, Bigelow DJ, Schoneich C. Protein modification during biological aging: selective tyr-osine nitration of the SERCA2a isoform of the sarcoplasmic reticulum Ca2R-ATPase in skeletal muscle. Biochem J 1999; 340 (Pt 3):657-669.
45. Xu KY, Huso DL, Dawson TM, Bredt DS, Becker LC. Nitric oxide synthase in cardiac sarcoplasmic reticulum. Proc Natl Acad Sci USA 1999; 96:657-662.
46. Xu L, Eu JP, Meissner G, Stamler JS. Activation of the cardiac calcium release channel (ryanodine receptor) by poly-S-nitrosylation. Science 1998; 279:234-237.
47. Gotoh T, Mori M. Nitric oxide and endoplasmic reticulum stress. Arterioscler Thromb Vasc Biol 2006; 26:1439-1446.
48. Fruhbeck G, Lopez M, Dieguez C. Role of caveolins in body weight and insulin resistance regulation. Trends Endocrinol Metab 2007; 18:177-182.
49. Fecchi K, Volonte D, Hezel MP, Schmeck K, Galbiati F. Spatial and temporal regulation of GLUT4 translocation by flotillin-1 and caveolin-3 in skeletal muscle cells. FASEB J 2006; 20:705-707.